The estimated Net Worth of John M. Hamm is at least $9.18 ezer dollars as of 23 November 2021. Mr Hamm owns over 3,800 units of Cumberland Pharmaceuticals stock worth over $9,181 and over the last 3 years he sold CPIX stock worth over $0.
Mr has made over 1 trades of the Cumberland Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 3,800 units of CPIX stock worth $8,930 on 23 November 2021.
The largest trade he's ever made was buying 3,800 units of Cumberland Pharmaceuticals stock on 23 November 2021 worth over $8,930. On average, Mr trades about 760 units every 0 days since 2021. As of 23 November 2021 he still owns at least 6,800 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Mr Hamm stock trades at the bottom of the page.
John Michael Hamm is the Director of Fin. & Accounting and CFO at Cumberland Pharmaceuticals.
Mr Hamm is 65, he's been the Director of Fin. & Accounting and CFO of Cumberland Pharmaceuticals since . There are 10 older and 9 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
John's mailing address filed with the SEC is 1600 WEST END AVENUE, SUITE 1300, , NASHVILLE, TN, 37203.
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv és Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include: